Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

An open-label, Phase I/II clinical trial of romaciclib (RVU120) as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)

Tomasz Sacha, Marcin Rymko, Katarzyna Dulik, Sebastian Grosicki, Rostislav Kuklík, Adam Falkowski, Nemanja Nikic, Gary Wilkinson, Ewelina Kowalewska, Agnieszka Szymula, Milena Mazan, Agnieszka Sroka-Porada, Tomasz Rzymski, Hendrik Nogai, Marta Sobas, Tomasz Wrobel, Aneta Szudy-Szczyrek

Blood (2025) 146 (Supplement 1): 2045.

https://doi.org/10.1182/blood-2025-2045

Published: 2025

Journal Articles

AI-powered precision: Unmasking hidden treatment optimizations for lower-risk myelodysplastic syndrome patients based on real-world, multi center EHR data.

Marek Dudziński, Anna Lason, Arkadiusz Sycz, Patryk Weglarz, Natalia Leonczuk, Lukasz Szukalski, Szymon Fornagiel, Grzegorz Helbig, Jaroslaw Piszcz, Marta Sobas, Agnieszka Pluta, Krzysztof Madry, Łukasz Brodowski, Grzegorz Basak, Michal J. Dabrowski, Karol Lis

Blood (2025) 146 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2025-6209

Published: 2025

Journal Articles

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Beatriz Martín Herreros, Irene Navarro Vicente, Milena Sitkiewicz, Pilar Lloret Madrid, Łukasz Targoński, Amparo Sempere, Joaquín Sánchez-García, Josefina Serrano, Manuel Perez Encinas, Jorge Labrador, Delfim Duarte, Tomás Rivero Equiza, Olga Salamero, Rafael Colmenares, Maria Teresa Cedena Romero, Tamara Castaño, Anna Armatys, Alberto Giménez Conca, Cristina Gil, Teresa Olave, Lorenzo Algarra, María García-Fortes, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Manuel Barrios García, Eduardo Rodríguez-Arbolí, Teresa Caballero-Velazquez, Dunia De Miguel, Fernanda Trigo, Joana Brioso Infante, Emilia Ulenberg, Bruno Paiva, Virginia Pradillo Fernandez, Mar Tormo, Victor Noriega Concepción, Teresa Bernal Del Castillo, Rolando Omar Vallansot, Mercedes Colorado, Lisette Costilla-Barriga, Matxalen Olivares Salaverri, Isabel Simón-Pilo, Nerea Caminos, Ada Esteban-Figuerola, Małgorzata Sobczyk-Kruszelnicka, Renata Guzicka-Kazimierczak, Krzysztof Lewandowski, Andrzej Szczepaniak, Santiago Cranco, Manuela Clavijo, Irene Rey, Magdalena Karasek, Antonio Solana-Altabella, Leticia Rapan, Marta Sobas, Pau Montesinos

Blood (2025) 146 (Supplement 1): 218.

https://doi.org/10.1182/blood-2025-218

Published: 2025

Journal Articles

Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

Blood (2025) 146 (Supplement 1): 217.

https://doi.org/10.1182/blood-2025-217

Published: 2025

Journal Articles

A multi-center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data

Anna Lason, Arkadiusz Sycz, Karol Lis, Patryk Weglarz, Lukasz Szukalski, Natalia Leonczuk, Szymon Fornagiel, Grzegorz Helbig, Marta Sobas, Jaroslaw Piszcz, Łukasz Brodowski, Agnieszka Pluta, Krzysztof Madry, Grzegorz Basak, Michal J. Dabrowski, Marek Dudziński

Blood (2025) 146 (Supplement 1): 5629.

https://doi.org/10.1182/blood-2025-5629

Published: 2025

Journal Articles

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

Blood (2025) 146 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2025-1021

Published: 2025

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Blood (2025) 146 (Supplement 1): 344.

https://doi.org/10.1182/blood-2025-344

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Blood (2024) 144 (Supplement 1): 844.

https://doi.org/10.1182/blood-2024-202362

Published: 2024

Journal Articles

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2024-203488

Published: 2024

Journal Articles

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Daniel C Choi, Nassima Messali, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Franco Castillo Tokumori, Katie Erdos, Joseph M. Scandura, Narasimha Rao Uda, Heidi Lischer, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao

Blood (2024) 144 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2024-212169

Published: 2024

Journal Articles

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Francesca Palandri, Marta Sobas, Claire Harrison, Raajit Rampal, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3191.

https://doi.org/10.1182/blood-2024-192908

Published: 2024

Journal Articles

Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Antonio Solana-Altabella, Irene Navarro Vicente, Marta Sobas, Josefina Serrano, Magdalena Karasek, Manuel Perez Encinas, Jorge Labrador, Cristina de la Fuente, Olga Salamero, Rafael Colmenares, Tamara Castaño, Lorenzo Algarra, María García-Fortes, Maria Dunia De Miguel, Fernanda Trigo, Delfim Duarte, Virginia Pradillo Fernandez, Maria Angeles Foncillas, Victor Noriega Concepción, Pedro Paúl Vidaller, Teresa Bernal Del Castillo, Juan Miguel Miguel Bergua Burgues, Gabriela Rodriguez Macias, Eduardo Rodriguez Arboli, Isabel Simon, Nerea Caminos, Ada Esteban-Figuerola, Joana Brioso Infante, Monica Alejandra Romero, Rolando Omar Vallansot, Lukasz Targonski, Emilia Ulenberg, Krzysztof Lewandowski, Anna Armatys, Renata Guzicka-Kazmierczak, Małgorzata Sobczyk-Kruszelnicka, Andrzej Szczepaniak, Beatriz De Rueda Ciller, Esperanza Lavilla-Rubira, Maria Paz Garrastazul Sánchez, Jackeline Solano Tovar, Cristina Insua Vilas, Maria Dolores Madrigal, Laura Lamarca Eraso, Mar Tormo, Carmen Botella, Mercedes Colorado, Manuel Barrios García, Rebeca Rodriguez-Veiga, Pilar Lloret Madrid, David Martinez Cuadron, Pau Montesinos

Blood (2024) 144 (Supplement 1): 320.

https://doi.org/10.1182/blood-2024-205106

Published: 2024

Journal Articles

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Irene Navarro Vicente, Antonio Solana-Altabella, Marta Sobas, Josefina Serrano, Magdalena Karasek, Manuel Perez Encinas, Jorge Labrador, Cristina de la Fuente, Olga Salamero, Rafael Colmenares Gil, Tamara Castaño, Jesús Lorenzo Algarra, María García-Fortes, Maria Dunia De Miguel, Fernanda Trigo, Delfim Duarte, Virginia Pradillo Fernandez, Maria Angeles Foncillas, Victor Noriega Concepcion, Pedro Paúl Vidaller, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Eduardo Rodriguez Arboli, Isabel Simon, Nerea Caminos, Ada Esteban-Figuerola, Joana Brioso Infante, Monica Alejandra Romero, Rolando Omar Vallansot, Lukasz Targonski, Emilia Ulenberg, Krzysztof Lewandowski, Anna Armatys, Renata Guzicka-Kazmierczak, Małgorzata Sobczyk-Kruszelnicka, Andrzej Szczepaniak, Beatriz De Rueda Ciller, Esperanza Lavilla, Maria Paz Garrastazul Sánchez, Jackeline Solano Tovar, Cristina Insua Vilas, Maria Dolores Madrigal Toscano, Laura Lamarca, Mar Tormo, Cristina Gil, Mercedes Colorado, Manuel Barrios García, Matxalen Olivares Salaverri, Lisette Costilla-Barriga, Rebeca Rodriguez Veiga, Pilar Lloret Madrid, David Martinez Cuadron, Pau Montesinos

Blood (2024) 144 (Supplement 1): 319.

https://doi.org/10.1182/blood-2024-205172

Published: 2024

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2024-208144

Published: 2024

Journal Articles

Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features

Amin T. Turki, Alberto Hernández Sánchez, Wellington Silva, Magdalena Karasek, Luca Guarnera, Koray Yalçin, Amir Enshaei, Marta Sobas, Dirk Reinhardt, Maria M Rivas, Deepak Kumar Mishra, Eduardo Rego, Ahmet Koc, Paola Núñez Medina, Maria Teresa Voso, Anthony Moorman, Felix Nensa, Merlin Engelke

Blood (2024) 144 (Supplement 1): 790.

https://doi.org/10.1182/blood-2024-207058

Published: 2024

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Kamil Brzozowski, Magdalena Czemerska, Marta Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan M. Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2023) 142 (Supplement 1): 5914.

https://doi.org/10.1182/blood-2023-181633

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

An open-label, Phase I/II clinical trial of romaciclib (RVU120) as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)

AI-powered precision: Unmasking hidden treatment optimizations for lower-risk myelodysplastic syndrome patients based on real-world, multi center EHR data.

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

A multi-center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only